Tags

Type your tag names separated by a space and hit enter

Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Metabolism. 2008 Sep; 57(9):1299-306.M

Abstract

Visceral obesity and insulin resistance are regarded as risk factors for atherosclerosis. Epidemiologic studies have demonstrated long-term anti-atherosclerotic effects with administration of alpha-glucosidase inhibitors. Alpha-glucosidase inhibitors also have been reported to enhance glucagon-like peptide 1 (GLP-1) secretion. We compared the postprandial effects of a single administration of miglitol and acarbose on glucose and lipid metabolism, on insulin requirement, on GLP-1 secretion, and on inflammatory and endothelial markers in viscerally obese subjects. Twenty-four viscerally obese subjects with relative insulin resistance participated in this study. Subjects were given a single dose of miglitol (50 mg), acarbose (100 mg), or placebo blindly and randomly before a meal in a crossover design. The meal loads after drug administration were tested 3 times within 2 weeks. We measured glucose, insulin, lipids, lipoprotein lipase, interleukin 6, intracellular adhesion molecule 1, vascular cell adhesion molecule 1, and active GLP-1 at before and various minutes after the meal. Single administration of both alpha-glucosidase inhibitors had several beneficial effects in improving postprandial hyperglycemia and reducing postprandial insulin requirement approximately 25% of placebo without adversely affecting lipid profiles. Although lipoprotein lipase levels within 2 hours after the meal did not show differences among miglitol, acarbose, and placebo administrations, miglitol significantly suppressed the increases in triglycerides, remnant-like particle triglycerides, and remnant-like particle cholesterol compared to acarbose and placebo in the early phase. Miglitol also significantly enhanced active GLP-1 secretion to a greater extent than acarbose (P < .01) and placebo (P < .001), and significantly suppressed the postprandial increase in interleukin 6 compared to placebo (P < .01). The results point to the potential suitability of miglitol as an anti-atherosclerotic effect in viscerally obese subjects, in preference to acarbose. Further studies are needed to elucidate the long-term effects on enhanced GLP-1 secretion and anti-atherosclerosis.

Authors+Show Affiliations

Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18702958

Citation

Arakawa, Masayuki, et al. "Miglitol Suppresses the Postprandial Increase in Interleukin 6 and Enhances Active Glucagon-like Peptide 1 Secretion in Viscerally Obese Subjects." Metabolism: Clinical and Experimental, vol. 57, no. 9, 2008, pp. 1299-306.
Arakawa M, Ebato C, Mita T, et al. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism. 2008;57(9):1299-306.
Arakawa, M., Ebato, C., Mita, T., Fujitani, Y., Shimizu, T., Watada, H., Kawamori, R., & Hirose, T. (2008). Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism: Clinical and Experimental, 57(9), 1299-306. https://doi.org/10.1016/j.metabol.2008.04.027
Arakawa M, et al. Miglitol Suppresses the Postprandial Increase in Interleukin 6 and Enhances Active Glucagon-like Peptide 1 Secretion in Viscerally Obese Subjects. Metabolism. 2008;57(9):1299-306. PubMed PMID: 18702958.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. AU - Arakawa,Masayuki, AU - Ebato,Chie, AU - Mita,Tomoya, AU - Fujitani,Yoshio, AU - Shimizu,Tomoaki, AU - Watada,Hirotaka, AU - Kawamori,Ryuzo, AU - Hirose,Takahisa, PY - 2008/02/06/received PY - 2008/04/22/accepted PY - 2008/8/16/pubmed PY - 2008/9/17/medline PY - 2008/8/16/entrez SP - 1299 EP - 306 JF - Metabolism: clinical and experimental JO - Metabolism VL - 57 IS - 9 N2 - Visceral obesity and insulin resistance are regarded as risk factors for atherosclerosis. Epidemiologic studies have demonstrated long-term anti-atherosclerotic effects with administration of alpha-glucosidase inhibitors. Alpha-glucosidase inhibitors also have been reported to enhance glucagon-like peptide 1 (GLP-1) secretion. We compared the postprandial effects of a single administration of miglitol and acarbose on glucose and lipid metabolism, on insulin requirement, on GLP-1 secretion, and on inflammatory and endothelial markers in viscerally obese subjects. Twenty-four viscerally obese subjects with relative insulin resistance participated in this study. Subjects were given a single dose of miglitol (50 mg), acarbose (100 mg), or placebo blindly and randomly before a meal in a crossover design. The meal loads after drug administration were tested 3 times within 2 weeks. We measured glucose, insulin, lipids, lipoprotein lipase, interleukin 6, intracellular adhesion molecule 1, vascular cell adhesion molecule 1, and active GLP-1 at before and various minutes after the meal. Single administration of both alpha-glucosidase inhibitors had several beneficial effects in improving postprandial hyperglycemia and reducing postprandial insulin requirement approximately 25% of placebo without adversely affecting lipid profiles. Although lipoprotein lipase levels within 2 hours after the meal did not show differences among miglitol, acarbose, and placebo administrations, miglitol significantly suppressed the increases in triglycerides, remnant-like particle triglycerides, and remnant-like particle cholesterol compared to acarbose and placebo in the early phase. Miglitol also significantly enhanced active GLP-1 secretion to a greater extent than acarbose (P < .01) and placebo (P < .001), and significantly suppressed the postprandial increase in interleukin 6 compared to placebo (P < .01). The results point to the potential suitability of miglitol as an anti-atherosclerotic effect in viscerally obese subjects, in preference to acarbose. Further studies are needed to elucidate the long-term effects on enhanced GLP-1 secretion and anti-atherosclerosis. SN - 1532-8600 UR - https://www.unboundmedicine.com/medline/citation/18702958/Miglitol_suppresses_the_postprandial_increase_in_interleukin_6_and_enhances_active_glucagon_like_peptide_1_secretion_in_viscerally_obese_subjects_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(08)00158-3 DB - PRIME DP - Unbound Medicine ER -